1 week Ago By Defense World Staff
American Century Companies Inc. raised its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) by 7.
5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 67,937 shares of the company’s stock after buying an additional 4,727 shares during the period. American Century Companies Inc.
owned about 0.19% of iTeos Therapeutics worth $522,000 as of its most recent SEC filing. Several other institutional investors and hedge funds also recently made changes to their positions in the stock.
Clear Harbor Asset Management LLC bought a new position in iTeos Therapeutics during the fourth quarter worth $96,000. Virtu Financial LLC bought a new position in shares of iTeos Therapeutics in the 3rd quarter worth about $102,000. SG Americas Securities LLC raised its position in shares of iTeos Therapeutics by 12.
2% in the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock worth $106,000 after acquiring an additional 1,508 shares in the last quarter. Marquette Asset Management LLC acquired a new position in shares of iTeos Therapeutics in the 4th quarter valued at about $122,000.
Finally, US Bancorp DE boosted its position in shares of iTeos Therapeutics by 40.1% during the 4th quarter. US Bancorp DE now owns 16,919 shares of the company’s stock valued at $130,000 after purchasing an additional 4,843 shares in the last quarter.
Institutional investors and hedge funds own 97.16% of the company’s stock. iTeos Therapeutics Stock Up 9.
1 %Shares of ITOS opened at $5.65 on Friday. The business’s fifty day moving average is $6.
74 and its 200 day moving average is $7.83. iTeos Therapeutics, Inc.
has a 12-month low of $4.80 and a 12-month high of $18.75.
The stock has a market cap of $215.80 million, a P/E ratio of -1.79 and a beta of 1.
43. iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($1.
01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.13.
On average, analysts expect that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.
Analyst Ratings ChangesA number of equities research analysts have weighed in on the company. Wells Fargo & Company lowered their target price on iTeos Therapeutics from $19.00 to $17.
00 and set an “overweight” rating for the company in a report on Thursday, March 6th. HC Wainwright reiterated a “buy” rating and set a $46.00 target price on shares of iTeos Therapeutics in a research report on Thursday, March 6th.
Wedbush restated an “outperform” rating and issued a $25.00 price target on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Finally, JPMorgan Chase & Co.
dropped their price objective on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th.
Check Out Our Latest Analysis on ITOSiTeos Therapeutics Company Profile (Free Report)iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Read MoreFive stocks we like better than iTeos TherapeuticsWhat is the S&P/TSX Index?Robinhood Strategies Could Be a Game-Changer for Young Investors10 Best Airline Stocks to BuyAre These 3 Retail Stocks Oversold or Really in Trouble?How to Evaluate a Stock Before Buying IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are AheadWant to see what other hedge funds are holding ITOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report).
.
